A chromosomal locus at 4q32.1 has been genomewide significantly associated with coronary artery disease risk. The locus encompasses GUCY1A3, which encodes the α 1 subunit of the soluble guanylyl cyclase (sGC), a key enzyme in the nitric oxide/cGMP signaling pathway. The mechanism linking common variants in this region with coronary risk is not known.
A n inherited component of the risk for developing atherosclerosis has been known for a long time. However, the underlying genetic mechanisms and causative genes are largely unknown. Genome-wide association studies (GWAS) identified 56 genomic loci associated with coronary artery disease (CAD) and myocardial infarction (MI) risk. [1] [2] [3] [4] [5] One of these is the GUCY1A3 locus. 3 Only a few CAD risk loci such as those harboring LDLR and PCSK9 [6] [7] [8] [9] contain mutations that were also found to cosegregate with CAD in a mendelian pattern of inheritance. We have recently observed such allelic series at the GUCY1A3 CAD risk locus for which a heterozygous loss-of-function allele was identified by linkage and a common variant by GWAS analysis to affect CAD risk. 3, 10 The GUCY1A3 gene encodes the α 1 subunit of the soluble guanylyl cyclase (sGC). The sGC complex, a heterodimer of the α 1 and a β 1 subunit, acts as the receptor for nitric oxide (NO) and catalyzes the formation of the second messenger cGMP. cGMP has several cellular functions, including the inhibition of platelet aggregation and smooth muscle cell (SMC) relaxation. 11 Further genetic evidence pointing to critical involvement of the NO-sGC-cGMP pathway in mediating CAD and MI risk has been provided by a recent GWAS meta-analysis that identified the NOS3 gene, encoding endothelial NO synthase, as a further CAD risk gene. 4 Whereas the variant at this locus has already been implicated to influence NOS3 expression, 12 the molecular mechanisms affected by common variants at the GUCY1A3 locus remain elusive.
Here, we provide functional evidence that the lead single-nucleotide polymorphism (SNP) at the chromosome 4q32.1 risk locus affects GUCY1A3 gene expression and give insights into the molecular disease mechanisms at the genetic and cellular levels.
METHODS

In Silico Analyses
SNPs in high linkage disequilibrium with the GUCY1A3 lead SNP were identified with SNP Annotation and Proxy Search. 13 The respective regions were analyzed for potential transcription factor binding sites with the University of California, Santa Cruz Genome Browser annotations.
14 Prediction of potential allele-specific binding of transcription factors was performed with AliBaba2.1 (http://www.gene-regulation. com/pub/databases.html). 15 
Human Samples and Cell Lines
Human Samples
Studies in samples from human individuals were performed after written informed consent was obtained. The ethics committee of the Technical University of Munich approved the protocol. All studies in human samples were in concordance with the Declaration of Helsinki. We included individuals who were treated at the German Heart Centre Munich. Whole-blood RNA was available in 4 homozygous nonrisk and risk allele carriers each. Platelet aggregation was studied in 8 and 14 homozygous nonrisk and risk allele carriers, respectively, who were not taking concurrent medication and displayed platelet counts in the normal range (150 000-400 000 per 1 µL).
Cell Lines
Human embryonic kidney (HEK) 293 cells, megakaryoblasts (both Sigma-Aldrich, St. Louis, MO), and human aortic endothelial cells (PromoCell, Heidelberg, Germany) are commercially available. Human aortic SMCs were either commercially purchased (PromoCell, Heidelberg, Germany) or part of the Systems Genetics Resource at the University of California, Los Angeles 16 (https://systems.genetics.ucla.edu/).
Isolation of Nucleic Acids and Genotyping
DNA from human samples was isolated from whole blood with the Gentra Puregene Blood Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Whole-blood RNA was isolated from PAXgene Blood RNA Tubes (PreAnalytiX, Hombrechtikon, Switzerland) with the PAXgene Blood RNA Kit (Qiagen, Hilden, Germany) as recommended by the suppliers. Genotyping was performed with a rs7692387 TaqMan Genotyping Assay (C__29125113_10; Life Technologies,
Clinical Perspective
What Is New?
• The mechanism underlying the association of common variants at the GUCY1A3 locus with coronary artery disease is elucidated.
• We show that the locus has regulatory properties with the risk allele leading to reduced expression of GUCY1A3.
• The GUCY1A3 lead single-nucleotide polymorphism (rs7692387) itself modulates binding of the transcription factor zinc finger E box-binding homeobox 1 resulting in reduced GUCY1A3 expression in carriers of the risk allele.
• As a consequence, risk allele carriers display impaired inhibition of vascular smooth muscle cell migration and platelet aggregation after stimulation of the soluble guanylyl cyclase.
What Are the Clinical Implications?
• The genotype-dependent effects found in this study contribute to the understanding of the genetic and functional relevance of soluble guanylyl cyclase activity for coronary artery disease and myocardial infarction risk.
• Modulating soluble guanylyl cyclase activity or inhibiting the resulting cellular effects caused by reduced expression of GUCY1A3 might be a promising therapeutic strategy for individuals at risk carrying GUCY1A3 risk alleles.
Carlsbad, CA) on a ViiA7 quantitative polymerase chain reaction (PCR) instrument (Life Technologies).
Murine Gucy1a3 Expression Analysis and Correlation With Plaque Formation
The Hybrid Mouse Diversity Panel has been described previously. 17 Briefly, Gucy1a3 genotype (rs30360584) was correlated with both aortic atherosclerotic lesion area and expression of the gene in heart tissue and aorta.
Expression Analysis of Transcription Factors
Expression of relevant transcription factors in distinct relevant tissues, that is, whole blood, mammary artery, and atherosclerotic arterial wall, was analyzed in data from the STAGE study (Stockholm Atherosclerosis Gene Expression). 18 Expression in cell lines, that is, HEK 293 cells, human aortic SMCs, human endothelial cells, and megakaryoblasts, was analyzed with reverse transcription PCR. Bands were visualized on agarose gels.
Reporter Gene Constructs and Assays
To study the regulatory role of the GUCY1A3 lead SNP (rs7692387) region, the GUCY1A3 promoter (2578 base pairs [ -length open-reading frame of zinc finger E box-binding homeobox 1 transcription factor (ZEB1) was amplified by Prime Star GXL proofreading polymerase (TaKaRa, Saint-Germain-en-Laye, France) and inserted into the 3xFLAG expression plasmid to obtain a ZEB1-3xFLAG fusion construct. Primers used for amplification are listed in Table I in the online-only Data Supplement. HEK 293 cells were seeded at 250 000 cells per well in 24-well plates and grown to confluence for 24 hours. Cells were cotransfected with 500 ng pGL4.10 constructs and 50 ng pRL-TK reporter vector with FuGENE HD Transfection Reagent (Promega Corp) in a concentration of 4:1. To investigate the effect of ectopically expressed ZEB1, 100 ng ZEB1 expression plasmid was added to each well. After 48 hours of incubation, cells were harvested and subsequently processed with the Dual-Luciferase Reporter Assay System (Promega Corp) according to the manufacturer's recommendations. Signals for Firefly and Renilla luciferase were measured on the Infinite M200 PRO reader (Tecan Group, Männedorf, Switzerland). Luciferase activities were normalized to Renilla signals and expressed as fold of the nonrisk variant.
Allele-Specific Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed with OneDay ChIP kit (Diagenode, Liège, Belgium) according to the manufacturer's protocol. Briefly, human aortic SMCs were crosslinked by adding formaldehyde to a 1% final concentration. After nuclei extraction, chromatin was sonicated with the Bioruptor pico (Diagenode, Liège, Belgium). Chromatin fragments were incubated with anti-ZEB1 antibody (Diagenode, Liège, Belgium) before agarose beads were added. Precipitated chromatin was purified by DNA-binding slurry and then treated with proteinase K. PCRgrade water was used to elute DNA from slurry. ZEB1 binding to the regulatory element including rs7692387 was verified by specific PCR-based amplification of the 407-bp regulatory element (chr4:155,713,878-155,714,284). SNaPshot multiplex PCR (Thermo Fisher Scientific, Carlsbad, CA) using 4 different oligo probes (F1-GGCCAAGGGCAGAGACATTT,
-CAGAGAACAAGA TTTGAAGATAGGTCTTT CTTTTT) was performed to quantify allele-specific binding of ZEB1.
ZEB1 Knockdown by RNAi
HEK 293 cells were seeded at a density of 250 000 cells per well in 24-well plates and grown to confluence; human aortic SMCs were seeded in 24-well plates at a density of 100 000 cells per well. Lipofectamine RNAiMAX Transfection Reagent (Life Technologies) was used for transfection according to the manufacturer's recommendations. Per well, 5 pmol siRNA ZEB1 (s229972; Life Technologies) was incubated with Lipofectamine RNAiMAX Transfection Reagent and Opti-MEM I Reduced Serum Medium (Gibco by Life Technologies) for 5 minutes at room temperature. Afterward, siRNARNAiMAX complexes were added to the cells and incubated for 24 hours. In parallel, cells were transfected with 5 pmol siRNA scramble as control (Silencer Select Negative Control No. 1 siRNA; Life Technologies). Cells were harvested after 24, 48, and 72 hours and forwarded to quantitative real-time PCR analysis (see below). For reporter gene assays after siRNA knockdown of ZEB1, HEK 293 cells were seeded at 250 000 cells per well in 24-well plates and grown to confluence for 24 hours. Cells were cotransfected with 500 ng pGL4.10 constructs and 50 ng pRL-TK reporter vector with the FuGENE HD Transfection Reagent (Promega Corp) in a concentration of 4:1. After 6 hours, cells were transfected with 5 pmol siRNA-ZEB1 or siRNA scramble . After 48 hours, cells were harvested and luciferase activity was measured as described above.
Quantitative Real-Time PCR
Total RNA was either isolated from whole blood as described above or extracted from cells with the RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA synthesis was performed with the ThermoScript reverse transcription-PCR System for First-Strand cDNA Synthesis Kit (Life Technologies) with a mixture of oligo(dT) and random hexamer primers. Expression levels were either determined with appropriate TaqMan Gene Expression probes or detected with PerfeCTa SYBR Green FastMix Low ROX (Quanta Biosciences, Gaithersburg, MD) with the primers and probes listed in Table II 
Aortic SMC Scratch Wound Assay
Migration was assessed with an in vitro scratch injury model. Human aortic SMCs derived from the Systems Genetics Resource at the University of California 16 were seeded in 24-well plates (50 000 cells per well) coated with 0.1% gelatin and grown to confluence for 24 hours. The cell monolayer was scratched in the middle with a p200 pipette tip (Gilson, Middleton, WI). Cells were then washed with PBS and incubated in SmBM Basal Medium supplemented with SmGM-2 SingleQuot Kit Supplement & Growth Factors (Lonza, Basel, Switzerland). Wound area was measured directly after scratch (t0) and after 5 hours (t1) with a phase-contrast microscope (EVOS FL Auto Cell Imaging System, Thermo Fisher Scientific, Waltham, MA) and assessed with ImageJ. 20 Wound reclosure was measured as Δt0-t1 under vehicle (dimethyl sulfoxide) and BAY 41-2272 (10 µmol/L; Cayman Chemical Co, Ann Arbor, MI) treatment for each genotype. Measurements were performed in triplicates in 5 independent experiments with passages P4 through P8 of the respective cell lines.
Platelet Response to NO
Preparation of Platelet-Rich Plasma
Whole-blood thrombocyte count was analyzed in EDTA blood samples with an automated hematology analyzer (Sysmex Corp, Köbe, Japan). All samples displayed thrombocyte counts in the normal range (150 000-400 000 per 1 µL). Platelet-rich plasma (PRP) was isolated after centrifugation of citrate blood for 10 minutes at 80g and room temperature without active deceleration. The supernatant containing PRP was transferred to fresh tubes, and the platelet count in PRP was measured to exclude significant deviations between samples. Platelet-poor plasma was isolated after centrifugation of the precipitate for 10 minutes at 3000g and room temperature. The supernatant containing platelet-poor plasma was transferred to fresh tubes.
Platelet Aggregation Analysis
Platelet aggregation analysis was performed according to the turbidimetric method of Born using a personal computercontrolled platelet aggregation profiler (PAP-8; Biodata Corp, Horsham, PA) as described previously. 21 Sodium nitroprusside (Carl Roth GmbH, Karlsruhe, Germany) and sildenafil (Sigma-Aldrich) were solved in dimethyl sulfoxide. Plateletpoor plasma of the respective proband was used for blanking of the measurement channels. Before induction of platelet aggregation, PRP samples were incubated with sodium nitroprusside (final concentration, 10 µmol/L) or sodium nitroprusside (final concentration, 10 µmol/L) plus sildenafil (final concentration, 10 µmol/L) for 2 minutes at 37°C. PRP incubated with H 2 O served as control and baseline measurement. All samples including the H 2 O control contained similar amounts of dimethyl sulfoxide (final concentration, 1:500). ADP (möLaboratory GmbH, Langenfeld, Germany) at a final concentration of 2 µmol/L was used to induce platelet aggregation. Platelet aggregation was recorded for 5 minutes after the addition of ADP. Area under the curve of platelet aggregation was the primary end point and displayed as arbitrary units times minutes.
Analysis of VASP Phosphorylation
Detection of phosphorylated VASP was performed as described previously. 21, 22 Briefly, after termination of platelet aggregation measurements, PRP samples were transferred to 1.5-mL tubes (Eppendorf AG, Hamburg, Germany) and centrifuged for 10 minutes at 20 000g and 4°C. Supernatant was discarded; 25 µL of 2× Laemmli buffer (Bio-Rad Laboratories) and 25 µL radioimmunoprecipitation assay buffer (SigmaAldrich) were added to the platelet pellet; and the samples were forwarded to immunoblotting.
Statistical Analysis
Distribution of data was assessed with the D'Agostino-Pearson omnibus normality test. Unless otherwise stated, normally distributed data were analyzed with the Student unpaired/ paired t test. Nonnormally distributed data were analyzed with the Mann-Whitney test. For comparison of >2 groups, ordinary 1-way ANOVA with the Tukey multiple-comparison test was used unless otherwise stated. Categorical data were analyzed with the Fisher exact test. Values of P<0.05 were regarded as significant. GraphPad Prism version 7.0a for Mac OS X (GraphPad Software, La Jolla, CA) was used.
RESULTS
Decreased GUCY1A3 Expression Is Associated With Atherosclerosis
Genotype-dependent GUCY1A3 expression was assessed in RNA extracts of whole-blood samples from 8 individuals. Homozygous risk allele carriers displayed significantly lower GUCY1A3 mRNA levels compared with homozygous nonrisk allele carriers ( Figure 1A) . To investigate whether these findings are conserved among different species, we identified a SNP affecting Gucy1a3 mRNA expression in mice in the Hybrid Mouse Diversity Panel (rs30360584). 17 As seen in human samples, the allele related to lower expression levels of Gucy1a3 in mice was associated with increased atherosclerotic disease burden ( Figure I in the onlineonly Data Supplement).
In Silico Predictions on the Human
GUCY1A3 Risk Variant
The lead SNP of the human CAD-GWAS meta-analysis, rs7692387, is located within intron 8 of the GUCY1A3 gene (NG_034128.1) on chromosome 4. We assessed properties of all variants in high linkage disequilibrium (r 2 >0.8) with the lead SNP variant (Table III in the onlineonly Data Supplement) using University of California, Santa Cruz Genome Browser annotations. 23 None of these variants were located in the coding region. Only the lead variant was found to be located at a DNase I hypersensitivity site (chr4:156,635,141-156,635,310 [HG19]; Figure II in the online-only Data Supplement) indicative of regulatory relevance. 24 Next, we screened in silico for putative transcription factor binding sites affected by rs7692387. In addition to the rather unspecific C/EBP transcription factor family, interferon regulatory factor 8 (IRF8) and ZEB1 were predicted to exhibit allele-specific binding. Whereas interferon regulatory factor 8 was predicted to bind only to the G allele, ZEB1 was predicted to bind to the A (nonrisk) allele (Table) . We then investigated the expression of IRF8 and ZEB1 in different cell lines in vitro and relevant tissues in the STAGE study.
18 ZEB1 was abundantly expressed in HEK 293 cells, human vascular SMCs, human endothelial cells, and megakaryoblasts ( Figure III in the online-only Data Supplement) but also in whole blood, mammary artery, and atherosclerotic arterial wall, that is, tissue relevant for sGC function (Table) . In contrast, IRF8 was not expressed in vascular SMC and megakaryoblasts. Publicly available genome-wide ChIP sequencing data generated on liver hepatocellular carcinoma cells 25 revealed binding of the transcription factor ZEB1 within the GUCY1A3 intronic region directly adjacent to rs7692387 ( Figure IVA in the online-only Data Supplement). We conducted ChIP experiments using formaldehyde-crosslinked chromatin of primary fibroblasts to confirm specific binding of ZEB1 to this genomic region. Therefore, a ChIP-grade anti-ZEB1 antibody was used for precipitation, followed by PCR amplification of a 407-bp fragment including the SNP rs7692387 (Figure IVB in the online-only Data Supplement). Thus, in consecutive experiments, we focused on the influence of ZEB1 on GUCY1A3 expression.
ZEB1 Modulates GUCY1A3 Expression
To assess regulatory properties of the GUCY1A3 lead SNP region, we performed reporter gene assays using constructs carrying the GUCY1A3 promoter and the nucleotide sequence containing the nonrisk or risk variant of rs7692387 ( Figure 1B) . Whereas the GUCY1A3 nonrisk allele construct (promoter [P]+A) led to a 25% increase of luciferase activity (P=0.0001), the risk allele construct (P+G) displayed a 20% reduction of luciferase activity compared with the construct carrying only the promoter (P<0.0005) and a 44% reduction of luciferase activity compared with the nonrisk allele construct (P<0.0001; Figure 1C ). As outlined above, in silico analysis predicted ZEB1 binding within the regulatory region with a binding affinity that might be directly correlated with the rs7692387 genotype. To address this, we performed allele-specific quantification of ZEB1-precipitated chromatin fractions using primer extension-based SNaPshot multiplex PCR in heterozygous vascular SMCs (VSMCs). Although the risk G allele and the nonrisk A allele were detected in both genomic DNA and chromatin fractions used for ChIP assays, ZEB1-precipitated chromatin fraction showed only the protective A allele, indicating exclusive ZEB1 binding to the A allele. (Figure 1D ). We further investigated the effect of ZEB1 knockdown on reporter gene expression. Using a specific RNA interference approach, we observed reduced ZEB1 mRNA levels by 46% (P=0.01) in HEK 293 cells and 80% (P=0.01) human aortic SMCs after 72 hours ( Figure 2A and 2B and Figures V and VI in the onlineonly Data Supplement), as well as reduced protein levels. Knockdown of ZEB1 led to a reduction in luciferase expression of the nonrisk (P+A) construct (15%; P<0.01; Figure 2C ) rather than the risk (P+G) construct (8%; P=0.05; Figure 2D ). In line with this finding, overexpression of ZEB1 resulted in an additional increase of reporter gene expression ( Figure 2E and 2F ). ZEB1-mediated activation was stronger for the construct containing the nonrisk variant (P+A; 65%; P<0.01; Figure 2E ) compared with the risk allele variant construct (P+G; 28%; P=0.0504; Figure 2F and Figure VII in the onlineonly Data Supplement). To further confirm these observations, we investigated endogenous GUCY1A3 mRNA levels in HEK 293 cells that were homozygous for the nonrisk variant (AA genotype). Knockdown of ZEB1 by siRNA led to a 25% decrease in GUCY1A3 expression after 72 hours (P<0.01; Figure 2G ). Because GUCY1A3 is endogenously expressed in vascular SMCs, we also investigated GUCY1A3 expression in human aortic SMC found to be heterozygous for rs7692387. Here, silencing of ZEB1 by RNAi also led to a significant reduction in GUCY1A3 expression (16%; P<0.01; Figure 2H ). 
GUCY1A3 Genotype Affects Human VSMC Migration After sGC Stimulation
To test whether the GUCY1A3 genotype influences vascular SMC migration, we performed a scratch wound assay in cells derived from a homozygous risk allele carrier and cells derived from a homozygous nonrisk allele carrier from the Systems Genetics Resource at UCLA. 16 The cell line homozygous for the risk allele (GG) displayed significantly reduced GUCY1A3 mRNA levels compared with a cell line derived from a homozygous nonrisk allele carrier (AA; Figure 3A) . We determined reclosure areas of the scratch wounds under vehicle treatment for the 2 cell lines and compared them with reclosure areas after treatment with the specific sGC stimulator BAY 41-2272. In the homozygous nonrisk allele donor cell line, a significant reduction in scratch wound reclosure was detected (P<0.01; Figure 3B and 3C), whereas BAY 41-2272 had no effect on migration in the cell line derived from the homozygous risk allele carrier ( Figure 3D and 3E ). VSMCs from a heterozygous individual displayed an intermediate effect ( Figure VIII in the online-only Data Supplement).
GUCY1A3 Genotype Affects NOMediated Inhibition of Platelet Function
Homozygous risk allele carriers displayed significantly reduced platelet α 1 sGC protein levels compared with homozygous nonrisk allele carriers (Figure 4) . To evaluate the functional implications of reduced α 1 sGC protein levels, we went on to analyze the enzymatic activity of sGC. Thus, we studied the production of its second messenger cGMP, which is known to inhibit platelet aggregation in PRP samples of homozygous nonrisk allele carriers (n=8) and homozygous risk allele carriers (n=14). Homozygous nonrisk allele carriers displayed slightly increased platelet counts (Table IV in the onlineonly Data Supplement). ADP-induced platelet aggregation was similar in homozygous risk allele and homozygous nonrisk allele carriers ( Figure 5A ). In contrast, the addition of sodium nitroprusside as a NO donor led to a stronger reduction of platelet aggregation in nonrisk compared with risk allele carriers (P<0.001; Figure 5B ). To confirm whether the effect was mediated via an accumulation of cGMP, we inhibited cGMP degradation by the additional supplementation of the phosphodiesterase 5 inhibitor sildenafil. The addition of sildenafil led to a further reduction of platelet aggregation in both genotypes with a stronger effect in homozygous nonrisk allele carriers (P<0.0001; Figure 5C ). NO application to platelets of individuals representing the 3 genotypes revealed that, with increasing numbers of nonrisk alleles, the inhibitory effect of NO became stronger (Figure IX in the online-only Data Supplement). To exclude an influence of prevalent atherosclerosis on platelet aggregation, we also analyzed the subgroups of individuals in whom atherosclerosis had been excluded by coronary angiography (Table V in 
GUCY1A3 Genotype Affects cGMP Levels in PRP
The observation that the addition of sildenafil enhanced the inhibition of platelet aggregation by the NO donor sodium nitroprusside points to a mechanism involving increased cGMP levels in platelets. To confirm this observation, we evaluated the cGMP-dependent phosphorylation of VASP by protein kinase G after measuring platelet aggregation in homozygous nonrisk and risk allele carriers (n=8 each). The addition of sodium nitroprusside led to increased phosphorylation of VASP at Serin 239 in homozygous nonrisk allele carriers compared with risk allele carriers (P<0.01). Again, this effect could be enhanced by the addition of the phosphodiesterase 5 inhibitor sildenafil, with significantly stronger cGMPdependent phosphorylation of VASP in homozygous nonrisk allele carriers compared with risk allele carriers (P=0.02; Figure 6 ).
DISCUSSION
In a series of experiments using human samples and cell lines, we provide evidence that SNP rs7692387, which is genome-wide significantly associated with CAD, is involved in the regulation of GUCY1A3 gene expression. The SNP is located at a DNase I hypersensitive region that overlaps an intron of the GUCY1A3 gene and interferes with ZEB1 in a genotype-specific manner. As a consequence of impaired GUCY1A3 expression, aortic SMCs of homozygous risk allele carriers showed decreased inhibitory effects of sGC stimulation on cell migration. We further observed that production of the second messenger cGMP and inhibition of platelet ag- ORIGINAL RESEARCH ARTICLE cally diverse mice. 17 The genotype-dependent effects found in this study might contribute to the understanding of the genetic and functional relevance of sGC activity for CAD and MI risk. 3 The impact of genetic variation in the GUCY1A3 gene on human atherosclerosis has been highlighted by previous studies that showed a unique digenic loss-offunction mutation affecting GUCY1A3 to cosegregate with CAD and MI in an extended family. 10 Besides, it has been shown that rare coding variants in the GUCY1A3 gene are enriched in patients with premature CAD and MI. 10, 21 Here, we investigated a risk variant for CAD and MI that has a high allele frequency in the population. 3 In fact, ≈60% of all Western Europeans are homozygous for the risk allele, whereas only ≈4% are homozygous for the nonrisk variant. Like most of the variants identified by GWAS, the GUCY1A3 risk variant rs7692387 appears to act through regulatory mechanisms rather than alterations of protein function or activity. 3 As has been shown for a variant at the SORT1 locus, 26 the nucleotide exchange in the risk compared with the nonrisk allele at this locus seems to lead to a modulation of the binding site for a transcription factor, that is, ZEB1, thereby directly affecting expression of the target gene.
ZEB1 is a transcription factor that may repress or activate transcription. 27 Missense mutations in ZEB1, also known as TCF8, have been associated with posterior polymorphous corneal dystrophy 28 and late-onset Fuchs corneal dystrophy 29 in humans. An increased prevalence of cardiovascular diseases has been reported in the latter disease. 30 ZEB1 also seems to play a role in vascular remodeling because mice with reduced levels of the murine counterpart displayed retarded differentiation of aortic SMC, although SMC differentiation marker genes, including Acta2 and Myh11, were still expressed. Whereas the total knockout was lethal, mice lacking 1 allele were vital and showed enhanced neointima formation after wire insertion-mediated injury compared with wildtype mice, 31 which is in agreement with our human data that suggest a higher risk for coronary atherosclerosis with less ZEB1-mediated GUCY1A3 expression.
Recently, the NOS3 gene encoding endothelial NO synthase has been identified to also be genome-wide significantly associated with CAD. 4 These results and our genetic and functional data presented here accentuate the impact of cGMP signaling in atherosclerosis. Targeting this pathway thus might represent a promising therapeutic strategy for patients with CAD or MI. Clinical studies investigating organic or inorganic nitrates for therapeutic sGC stimulation in cardiovascular diseases, for example, NITRITE-AMI (Safety and Effectiveness of Intra-Coronary Nitrite in Acute Myocardial Infarction) and NIAMI (Nitrites in Acute Myocardial Infarction), revealed contradictory results, 32, 33 potentially because of enhanced oxidative stress by the study medication. Rather than administration of NO donors, direct targeting of sGC might thus be a promising therapeutic strategy. Indeed, a number of sGC activators and stimulators 34 are available and approved for the treatment of, for example, pulmonary hypertension. 35 In addition, the NO-independent sGC activator cinaciguat has already been shown to display beneficial effects in an ischemia/ reperfusion injury model. 36 Several limitations of this study have to be taken into account. First, it was not possible to show an increase of GUCY1A3 expression by overexpressing ZEB1, which was due to the strong expression of ZEB1 in every cell line tested. Second, VSMC migration and platelet function experiments presented in this study do not fully resemble the in vivo human situation. In particular, it was not possible to study a large set of VSMCs carrying both genotypes. Nevertheless, the data uniformly point toward a stronger effect of NO on inhibition of migration and platelet aggregation in GUCY1A3 nonrisk allele carriers. Third, a recently published article suggests that complete knockout of Gucy1a3 in mice may reduce atherosclerotic plaque formation on a proatherogenic background (Ldlr −/− ). 37 In contrast to this study, we and others investigated a partial loss of sGC activity and showed experimentally in mice and functionally in human materials that this leads to increased disease risk. 10, [38] [39] [40] Thus, in the total Gucy1a3 knockout model, compensatory mechanisms affecting NO/cGMP signaling, including a marked compensatory increase of Gucy1a2 expression in Gucy1a3 −/− VSMCs, 37 may not have been adequately addressed. Indeed, the total knockout of genes might be more useful to investigate molecular mechanisms rather than complex diseases such as atherosclerosis. As an example, a recent analysis of murine knockout models associated with an atherosclerotic phenotype revealed only limited overlap compared with human genetic data from CAD GWAS. 41 The mouse population approach used by the Hybrid Mouse Diversity Panel 17 might be more informative in this regard because it is able to discriminate gene expression in mice quantitatively rather than qualitatively. Data from this resource are concordant with our findings on the human risk allele at the GUCY1A3 locus.
Taken together, the extensive genetic and functional data illustrated here document for the first time that a common variant in the GUCY1A3 gene affects sGC expression, SMC migration, and platelet function. In conjunction with human genetic data 3, 10 it can be concluded that dysregulation of sGC activity increases coronary risk. Phosphorylation of VASP by the cGMP-dependent protein kinase G (PKG) was assessed via Western blot. PKG-dependent phosphorylation of VASP was stronger in homozygous nonrisk allele carriers (n=8) after addition of the nitric oxide (NO) donor sodium nitroprusside (P<0.01). After addition of sildenafil to sodium nitroprusside, homozygous nonrisk allele carriers (n=8) still displayed significantly stronger phosphorylation (P) of VASP compared with homozygous risk allele carriers (n=8; P=0.02). Mann-Whitney test. Data are median and interquartile range.
